Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
I'm 18 and founded an AI startup. I have to wake up at 3 a.m. to work on it before school, but it's worth every sleepless night. - 2The 25 Most Notable Style Crossroads in History
- 3The architect of Iran’s military survival remains defiant
- 4Vote in favor of Your #1 sort of pie
- 5How to watch 2026 Golden Globe winners like 'One Battle After Another,' 'Adolescence' and 'The Pitt'
- The Most Vital Crossroads in Olympic History
- US measles cases surpass 2,000, highest in 30 years: CDC
- Figuring out the Business venture Code: The Response to Building an Effective Startup
- 7 Moves toward a Sound and Dynamic Way of life
- A new mom skipped a routine appointment. An infected cut led to a devastating diagnosis
- 6 Solid Moving Administrations for a Calm Movement
- Step by step instructions to Streamline Your Dozing Involvement in a Savvy Bed
- From ‘Project Hail Mary’ to Artemis II, spaceflight captures audiences when it centers on people because human space travel is hazardous
- Novo Nordisk slashes prices of popular weight loss and diabetes drugs
